About the Study
This study is designed to evaluate the safety and effectiveness of IPN10200, a novel injection, for preventing episodic and chronic migraine in adults. Participants will receive a single treatment cycle through a series of small injections in the head and neck muscles.
The study is randomized, double-blind, and placebo-controlled to ensure high-quality, unbiased results. If you qualify and choose to participate, there is a 66% chance you will receive the study treatment and a 33% chance you will receive a placebo. A placebo is an inactive material that looks like IPN10200 but does not contain any active ingredient.
You will be on this study for approximately 40-42 weeks which will include a screening period, a treatment period, and a follow up period. The study will require up to 7 in-clinic visits and 7 remote visits. If you qualify and choose to participate, you will be compensated up to $1,050 for in-clinic and remote visits as well as reimbursed for travel and accommodations when necessary. Your participation is entirely voluntary, and you can leave the study at any time.